Alert: We're here for you. Learn how COVID-19 may affect your mesothelioma treatment and doctor appointments.

Dr. Michael Kashgarian

Dr. Michael Kashgarian

Professor and Senior Research Scientist

There is no substitute for experience. And Dr. Michael Kashgarian, dubbed a renaissance man for the magnitude and diversity of his work, is living proof of this.

Get in touch
Jump to a Topic:

About Michael Kashgarian

  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Research Excellence icon

    Excellence in Research

  • Mesothelioma Pioneer icon

    Mesothelioma Pioneer

  • 50+ Years of Experience icon

    50+ Years of Experience

Using more than 50 years to study diseases and cancers like mesothelioma, Dr. Michael Kashgarian became one of the world’s most respected research scientists. Now a professor emeritus of pathology as well as a senior research scientist, Kashgarian remains a part of the work he completed at Yale, serving as the pioneer that others are following.

Now retired, he is still certified by the Anatomic & Clinical Pathology Board and Medicolegal Pathology, and he is considered an authority in diagnosing mesothelioma patients. This diagnosis helps determine the legal standing of patients fighting for financial compensation to cover disease expenses.

Long History of Mesothelioma Research

Kashgarian also conducted research on mesothelioma, providing explanations as to why treatments that were effective for some cancers did not seem to work for people with mesothelioma.

He has published articles in the Journal of Clinical Endocrinology & Metabolism, the Journal of the American Society of Nephrology, Cytoskeleton, Immunity, the Journal of Immunology, Biochimica et Biophysica Acta and others.

Among the areas of his research were the pathologies of thoracic cancers, including mesothelioma. His pathology work helped the medical community find new surgery techniques, new ways to give radiation therapy and new drugs to use in combination with radiation therapy. The developments in all those areas were applied to a number of cancer treatments.

In addition to gathering research, Kashgarian led a group of doctors searching for records of the first use of intravenous chemotherapy for cancer, which occurred in 1942 at Yale School of Medicine. Finding this historical information helped to credit the original researchers who developed chemotherapy during preparations for chemical warfare.

Doctor talking to patients

Find a Mesothelioma Doctor

Connect with top mesothelioma doctors and cancer centers to get the best treatment.

Find a Doctor

Influence on Other Mesothelioma Researchers

Kashgarian also helped build a diagnostic renal pathology and electron microscopy laboratory at Yale. That lab is named for him. A colleague of 30 years, Jon Morrow, Ph.D., M.D., described his passion for understanding renal disease as inspiring. Morrow went on to say that Kashgarian “profoundly affected the practice of physiology.”

Kashgarian influenced the work and development of other colleagues as well. The 2002 president of the American Society of Nephrology, Norman Siegel, commended Kashgarian for his mentorship. Siegel said Kashgarian pushed him to continue gaining more experience, even after early experiments fail.

The Renal Pathology Society awarded Kashgarian with the Jacob Churg Award in 2004 for his contributions to the field of nephropathology. The award is named after a pathologist who conducted studies linking asbestos exposure to mesothelioma. Kashgarian was the eighth recipient of the award, which comes with a monetary gift from Barnert Hospital.

Quick Fact:

In addition to English, Dr. Kashgarian is fluent in Armenian, French and German.

In 2010, Kashgarian was the centerpiece of a Yale medical symposium honoring his decades of wide-ranging work and the roles he took on as clinician, investigator and teacher.

In recent years, Kashgarian has contributed to research that focuses on the genetic composition of mesothelioma.

See More Top Mesothelioma Doctors

Dr. Kashgarian’s Publications

Kashgarian’s feature publications have discussed relevant issues in immunology and tissue damage after cancer treatment.

Disclaimer: Dr. Michael Kashgarian has no professional affiliation with

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer. Mesothelioma Packet

Get a Free Treatment Guide Sent Overnight

Get Yours Now

Find Ways to Pay for Treatment Costs

Get Started

Find an Active Mesothelioma Clinical Trial

Find Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Walter Pacheco, Managing Editor at
Edited by

6 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. Yale Medical Group. (2012). Michael Kashgarian. Retrieved from:
  2. Yale School of Medicine. (2012). Michael Kashgarian. Retrieved from:
  3. Schiff, J. (2011 June). Pioneers in Chemotherapy. Yale Alumni Magazine. Retrieved from:
  4. Siegel, N. (2003). Presidential Address: a time for morphogenesis, growth, and development. Journal of the American Society of Nephrology, 15:4. Retrieved from:
  5. Mount Sinai School of Medicine. (2012). Department of Pathology. Retrieved from:
  6. Yale School of Medicine. (2012). Pathologist honored with symposium. Retrieved from:

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified August 26, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now